Efficacy of chemotherapy combined with immunotherapy in advanced lung adenocarcinoma harboring epidermal growth factor receptor

Ying Zhao, Xiujing Yao, Ruyue Li, Xue Dong, Ying Li, Yintao Li

Abstract read

In one paragraph

Article in Cancer pathogenesis and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ying ZhaoDepartment of Respiratory Oncology, Shandong Cancer Hospital and Institute, Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang, Shandong 261000, China.

Xiujing YaoDepartment of Respiratory Oncology, Shandong Cancer Hospital and Institute, Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang, Shandong 261000, China.

Ruyue LiDepartment of Respiratory Oncology, Shandong Cancer Hospital and Institute, Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang, Shandong 261000, China.

Xue DongDepartment of Respiratory Oncology, Shandong Cancer Hospital and Institute, Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang, Shandong 261000, China.

Ying LiDepartment of Respiratory Oncology, Shandong Cancer Hospital and Institute, Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang, Shandong 261000, China.

Yintao LiDepartment of Respiratory Oncology, Shandong Cancer Hospital and Institute, Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang, Shandong 261000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although chemotherapy combined with immunotherapy is effective in advanced non-small cell lung cancer (NSCLC), its efficacy in patients with epidermal growth factor receptor Methods: This retrospective analysis included 66 patients: 28 received chemotherapy plus immunotherapy, and 38 received chemotherapy alone. The primary endpoint was progression-free survival (PFS), and the secondary endpoint was safety. In eligible patients with measurable disease, tumor response was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. PFS was defined as the time from the first day of therapy to disease progression or death from any cause. Results: The median progression-free survival (mPFS) was 10.5 months (95% confidence interval (CI): 7.03-16.63 months) in the chemotherapy plus immunotherapy group and 6.23 months (95% CI: 4.53-7.07 months) in the chemotherapy alone group. There was a significant difference in efficacy between the chemotherapy plus immunotherapy and chemotherapy-alone groups ( Conclusions: First-line chemotherapy combined with immunotherapy was associated with significantly longer PFS than chemotherapy alone in patients with

Indexed as

Adverse eventsCarcinomaEpidermal growth factorImmunotherapyMutationNon-small cell lungReceptorSurvival analysis

Identifiers

PMID41809570

DOI10.1016/j.cpt.2025.09.001

PMCPMC12969423

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.